va glp 1 coverage Pentagon Drops of GLP-1 Weight Loss Meds for Medicare-Eligible Retirees Designing fiscally viable coverage of

A priority setting partnership between patients and healthcare professionals

How These Results Compare to Other Weight Loss Medicines Retatrutide's 24.2% mean weight loss at 48 weeks exceeds phase 3 data for semaglutide 2.4 mg (~14.9% at 68 weeks) and is comparable to tirzepatide 15 mg (~22.5% at 72 weeks), though no direct head-to-head trials have been conducted

But for many Americans, the issue taps into something deeper years of frustration with a system they say feels stacked against them, where prices are hard to track and its not always clear if theyre getting a fair deal

[DOI] [PubMed] [Google Scholar] 46.Vallf D., Vestlund J., Jerlhag E

What About Ozempic